Published in Cancer Weekly, October 21st, 1996
The patent covers numerous antisense sequences targeted to C-raf kinase, most notable of which is the sequence of ISIS 5132/CGP69846A, and includes broad claims covering analogs of these compounds incorporating a variety of novel chemical modifications which have the potential to produce antisense compounds with enhanced potency and safety and altered pharmacokinetics.
The inventors on the patent were Brett P. Monia, Ph.D., and Russell Boggs, Ph.D., Isis. ISIS 5132/CGP69846A has been in Phase I clinical trials as a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.